| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 17.84M | 5.51M | 1.32M | 30K | 89.15M |
| Revenue Growth % | - | - | - | -0.69% | -0.76% | -0.98% | 2970.63% |
| Cost of Goods Sold | 1.42M | 1.55M | 14.07M | 213K | 0 | 0 | 20.56M |
| COGS % of Revenue | - | - | 0.79% | 0.04% | - | - | 0.23% |
| Gross Profit | -1.42M | -1.55M | 3.77M | 5.29M | 1.32M | 30K | 68.59M |
| Gross Margin % | - | - | 0.21% | 0.96% | 1% | 1% | 0.77% |
| Gross Profit Growth % | - | -0.09% | 3.44% | 0.41% | -0.75% | -0.98% | 2285.4% |
| Operating Expenses | 16.9M | 22.52M | 4.23M | 24.75M | 36.83M | 67.55M | 71.67M |
| OpEx % of Revenue | - | - | 0.24% | 4.49% | 27.99% | 2251.67% | 0.8% |
| Selling, General & Admin | 2.1M | 1.02M | 4.23M | 4.69M | 18.46M | 47.28M | 0 |
| SG&A % of Revenue | - | - | 0.24% | 0.85% | 14.02% | 1576.13% | - |
| Research & Development | 14.8M | 21.5M | 14.07M | 20.27M | 18.38M | 20.27M | 19.58M |
| R&D % of Revenue | - | - | 0.79% | 3.68% | 13.96% | 675.53% | 0.22% |
| Other Operating Expenses | 0 | 0 | -14.07M | -213K | 0 | 0 | 52.09M |
| Operating Income | -18.32M | -24.07M | -469K | -19.45M | -35.52M | -67.52M | -3.08M |
| Operating Margin % | - | - | -0.03% | -3.53% | -26.99% | -2250.67% | -0.03% |
| Operating Income Growth % | - | -0.31% | 0.98% | -40.48% | -0.83% | -0.9% | 0.95% |
| EBITDA | -16.9M | -22.52M | -463K | -19.24M | -35.2M | -67.45M | -3M |
| EBITDA Margin % | - | - | -0.03% | -3.49% | -26.75% | -2248.23% | -0.03% |
| EBITDA Growth % | - | -0.33% | 0.98% | -40.56% | -0.83% | -0.92% | 0.96% |
| D&A (Non-Cash Add-back) | 1.42M | 1.55M | 6K | 213K | 319K | 73K | 79K |
| EBIT | -17.58M | -23.97M | -469K | -19.45M | -35.52M | -67.52M | -3.08M |
| Net Interest Income | 0 | 100K | 371K | 694K | 0 | 0 | 0 |
| Interest Income | 43K | 100K | 400K | 800K | 0 | 0 | 0 |
| Interest Expense | 0 | - | 29K | 106K | 0 | 0 | 0 |
| Other Income/Expense | 741K | 100K | -596K | -789K | 834K | 13.15M | 11.37M |
| Pretax Income | -17.58M | -23.97M | -1.06M | -20.24M | -34.68M | -54.37M | 8.29M |
| Pretax Margin % | - | - | -0.06% | -3.68% | -26.35% | -1812.17% | 0.09% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 288K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 0.97% |
| Net Income | -17.58M | -23.97M | -1.06M | -20.24M | -34.68M | -54.37M | 8M |
| Net Margin % | - | - | -0.06% | -3.68% | -26.35% | -1812.17% | 0.09% |
| Net Income Growth % | - | -0.36% | 0.96% | -18.01% | -0.71% | -0.57% | 1.15% |
| Net Income (Continuing) | -17.58M | -23.97M | -1.06M | -20.24M | -34.68M | -54.37M | 8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.53 | -0.72 | -0.03 | -0.70 | -0.87 | -0.57 | 0.08 |
| EPS Growth % | - | -0.36% | 0.96% | -21.8% | -0.24% | 0.34% | 1.14% |
| EPS (Basic) | -0.53 | -0.72 | -0.03 | -0.70 | -0.87 | -0.57 | 0.08 |
| Diluted Shares Outstanding | 33.07M | 33.07M | 34.7M | 28.87M | 39.96M | 95.22M | 102.39M |
| Basic Shares Outstanding | 33.07M | 33.07M | 34.7M | 28.87M | 39.96M | 95.22M | 96.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 20.78M | 10.53M | 26.38M | 60.73M | 277.7M | 231.56M | 334.3M |
| Cash & Short-Term Investments | 20.16M | 9.98M | 24.52M | 60.06M | 274.38M | 228.36M | 314.02M |
| Cash Only | 20.16M | 9.98M | 24.52M | 60.06M | 210.52M | 70.97M | 50.82M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 63.86M | 157.39M | 263.2M |
| Accounts Receivable | 0 | 0 | 384K | 1K | 0 | 795K | 9.16M |
| Days Sales Outstanding | - | - | 7.86 | 0.07 | - | 9.67K | 37.51 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 5.21M |
| Days Inventory Outstanding | - | - | - | - | - | - | 92.54 |
| Other Current Assets | 618K | 552K | 0 | 0 | 1.01M | 0 | 1.23M |
| Total Non-Current Assets | 6.77M | 5.12M | 25K | 716K | 3.73M | 1.63M | 16.86M |
| Property, Plant & Equipment | 6.02M | 4.57M | 23K | 693K | 774K | 824K | 1.07M |
| Fixed Asset Turnover | - | - | 775.43x | 7.95x | 1.70x | 0.04x | 83.63x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 7.68M |
| Long-Term Investments | 750K | 550K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 2K | 23K | 2.96M | 801K | 8.11M |
| Total Assets | 27.55M | 15.65M | 26.41M | 61.45M | 281.44M | 233.19M | 351.15M |
| Asset Turnover | - | - | 0.68x | 0.09x | 0.00x | 0.00x | 0.25x |
| Asset Growth % | - | -0.43% | 0.69% | 1.33% | 3.58% | -0.17% | 0.51% |
| Total Current Liabilities | 5.14M | 17.93M | 8.21M | 8.19M | 5.44M | 2.39M | 23.44M |
| Accounts Payable | 775K | 3.52M | 1.22M | 1.79M | 1.66M | 759K | 9.87M |
| Days Payables Outstanding | 199.21 | 830.58 | 31.62 | 3.06K | - | - | 175.25 |
| Short-Term Debt | 3.53M | 12.3M | 2.56M | 3.48M | 0 | 237K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 0 | 0 | 557K |
| Other Current Liabilities | 841K | 2.11M | 0 | 660K | 1.46M | 1.08M | 2.29M |
| Current Ratio | 4.04x | 0.59x | 3.21x | 7.42x | 51.01x | 96.85x | 14.26x |
| Quick Ratio | 4.04x | 0.59x | 3.21x | 7.42x | 51.01x | 96.85x | 14.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | -45.19 |
| Total Non-Current Liabilities | 4.21M | 3.32M | 32.25M | 84.53M | 3.1M | 37K | 70.92M |
| Long-Term Debt | 0 | 0 | 7.46M | 4.93M | 0 | 0 | 0 |
| Capital Lease Obligations | 4.21M | 3.32M | 0 | 480K | 251K | 37K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 21.35M | 76.12M | 2.85M | 0 | 69.38M |
| Total Liabilities | 9.35M | 21.25M | 40.46M | 92.72M | 8.55M | 2.43M | 94.36M |
| Total Debt | 7.73M | 15.62M | 10.02M | 9.03M | 481K | 274K | 42K |
| Net Debt | -12.43M | 5.64M | -14.5M | -51.03M | -210.04M | -70.7M | -50.77M |
| Debt / Equity | 0.43x | - | - | - | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -16.17x | -183.53x | - | - | - |
| Total Equity | 18.2M | -5.6M | -14.05M | -31.27M | 272.89M | 230.76M | 256.8M |
| Equity Growth % | - | -1.31% | -1.51% | -1.23% | 9.73% | -0.15% | 0.11% |
| Book Value per Share | 0.55 | -0.17 | -0.40 | -1.08 | 6.83 | 2.42 | 2.51 |
| Total Shareholders' Equity | 18.2M | -5.6M | -14.05M | -31.27M | 272.89M | 230.76M | 256.8M |
| Common Stock | 0 | 0 | 223K | 3K | 9K | 10K | 10K |
| Retained Earnings | -39.82M | -63.79M | -22.01M | -42.26M | -76.94M | -131.3M | -123.31M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 407K | 49K | 220K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.88M | -18.9M | 9.07M | -17.56M | -40.08M | -59.27M | 13.55M |
| Operating CF Margin % | - | - | 0.51% | -3.19% | -30.45% | -1975.53% | 0.15% |
| Operating CF Growth % | - | -0.12% | 1.48% | -2.94% | -1.28% | -0.48% | 1.23% |
| Net Income | -17.58M | -23.97M | -1.06M | -20.24M | -34.68M | -54.37M | 8M |
| Depreciation & Amortization | 1.42M | 1.55M | 6K | 213K | 319K | 73K | -7.17M |
| Stock-Based Compensation | 0 | 0 | 3.54M | 2.83M | 5.84M | 9.23M | 14.53M |
| Deferred Taxes | 0 | 0 | 1K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.04M | 223K | 121K | -4K | 1.2M | -6.88M | 0 |
| Working Capital Changes | -433K | 3.3M | 6.46M | -356K | -12.75M | -7.33M | -1.81M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -8.18M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -5.95M |
| Change in Payables | 513K | 4.01M | 1.79M | 0 | -10.29M | -2.78M | 16.43M |
| Cash from Investing | -449K | -96K | -917K | -55K | -199K | -87.18M | -106.1M |
| Capital Expenditures | -449K | -96K | -917K | -55K | -199K | -175K | -563K |
| CapEx % of Revenue | - | - | 0.05% | 0.01% | 0.15% | 5.83% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -7.5M |
| Cash from Financing | 19.4M | 8.61M | 5.1M | 53.16M | 190.73M | 6.9M | 72.4M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -409.11M | 169K | 198.84M | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -17.32M | -18.99M | 8.15M | -17.62M | -40.28M | -59.44M | 12.98M |
| FCF Margin % | - | - | 0.46% | -3.2% | -30.61% | -1981.37% | 0.15% |
| FCF Growth % | - | -0.1% | 1.43% | -3.16% | -1.29% | -0.48% | 1.22% |
| FCF per Share | -0.52 | -0.57 | 0.23 | -0.61 | -1.01 | -0.62 | 0.13 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.79x | -8.52x | 0.87x | 1.16x | 1.09x | 1.69x |
| Interest Paid | 0 | 0 | 325K | 576K | 366K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -96.6% | -380.61% | - | - | -28.71% | -21.59% | 3.28% |
| Return on Invested Capital (ROIC) | - | -621.14% | - | - | - | -45.43% | -1.26% |
| Gross Margin | - | - | 21.11% | 96.13% | 100% | 100% | 76.94% |
| Net Margin | - | - | -5.97% | -367.65% | -2635.41% | -181216.67% | 8.97% |
| Debt / Equity | 0.43x | - | - | - | 0.00x | 0.00x | 0.00x |
| Interest Coverage | - | - | -16.17x | -183.53x | - | - | - |
| FCF Conversion | 0.96x | 0.79x | -8.52x | 0.87x | 1.16x | 1.09x | 1.69x |
| Revenue Growth | - | - | - | -69.13% | -76.1% | -97.72% | 297063.33% |
| 2024 | |
|---|---|
| Product | 7.25M |
| Product Growth | - |
ARS Pharmaceuticals, Inc. (SPRY) has a price-to-earnings (P/E) ratio of 142.0x. This suggests investors expect higher future growth.
ARS Pharmaceuticals, Inc. (SPRY) reported $142.8M in revenue for fiscal year 2024.
ARS Pharmaceuticals, Inc. (SPRY) grew revenue by 297063.3% over the past year. This is strong growth.
ARS Pharmaceuticals, Inc. (SPRY) reported a net loss of $80.0M for fiscal year 2024.
ARS Pharmaceuticals, Inc. (SPRY) has a return on equity (ROE) of 3.3%. This is below average, suggesting room for improvement.
ARS Pharmaceuticals, Inc. (SPRY) had negative free cash flow of $86.0M in fiscal year 2024, likely due to heavy capital investments.